Evidence map›Paper›PMID 42316276›Full record

ArticleGenome medicine2026

VariantMedium: sensitive and generalizable somatic point mutation calling with 3D DenseNets trained and evaluated on experimental data.

Özlem Muslu, Thomas Bukur, Pablo Riesgo-Ferreiro, Sameesh Kher, Shaya Akbarinejad, Luis Kress, Stefania Gangi Maurici, Muhammad Nabeel Asim, Alina Henrich, Sheraz Ahmed and 4 more

Abstract read
In one paragraph

Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Özlem MusluTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Thomas BukurTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Pablo Riesgo-FerreiroTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Sameesh KherTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Shaya AkbarinejadTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Luis KressTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Stefania Gangi MauriciTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Muhammad Nabeel AsimDeutsches Forschungszentrum für künstliche Intelligenz GmbH, Kaiserslautern, Germany.
Alina HenrichTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Sheraz AhmedDeutsches Forschungszentrum für künstliche Intelligenz GmbH, Kaiserslautern, Germany.
Andreas DengelDeutsches Forschungszentrum für künstliche Intelligenz GmbH, Kaiserslautern, Germany.
Martin LöwerTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany.
Jonas Ibn-SalemTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany. jonas.ibn-salem@tron-mainz.de.
Ugur SahinTRON - Translational Oncology at the University Medical Center of Johannes Gutenberg, University gGmbH, TRON gGmbH, Freiligrathstraße 12, Mainz, D-55131, Germany. sahin@uni-mainz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurately identifying somatic variants from genomic sequencing is crucial for understanding and treating cancer. Previously, methods based on statistics and heuristics, as well as methods based on machine learning were proposed for somatic single nucleotide variant (SNV) calling from matched tumor-normal data, but they suffer from low sensitivity especially in certain genomic regions.

methodsHere we present VariantMedium, a somatic variant caller that combines a tree-based classifier with a 3D densely connected convolutional network (DenseNet) architecture. We trained and evaluated our model on experimentally confirmed variant data and improved it with an active learning strategy by experimentally confirming the predicted variants via targeted deep sequencing experiments. Overall, we used 336,839 variants from 2,956 samples with whole exome or genome sequencing for training and validation, and 118,887 variants from two independent studies with deep sequencing data for evaluation and benchmarking.

resultsVariantMedium shows highest sensitivity amongst benchmarked callers and achieves similar or better F1 scores in SNV calling. Its performance is particularly pronounced on genomic regions characterized by high sequencing error rates, achieving higher F1 scores than Mutect2 and Strelka2.

conclusionsOur results demonstrate the strength of combining machine learning with high-quality experimental confirmation, enabling accurate somatic mutation detection even in low-mappability regions. We provide VariantMedium ( https://github.com/TRON-Bioinformatics/VariantMedium ) as an end-to-end pipeline to advance somatic mutation calling for precision medicine.

Indexed as

NeoplasmsPoint MutationSoftwareAlgorithmsComputational BiologyConvolutional Neural NetworksGenomicsHigh-Throughput Nucleotide SequencingHumansPolymorphism, Single NucleotideDeep learningMachine learningOpen source softwarePrecision oncologySingle nucleotide variantSomatic call benchmarkingSomatic mutationSomatic SNVSomatic variant callingTumor-normal sequencing

Identifiers

PMID42316276
PMCPMC13285312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.